While it is widely agreed upon that a Hillary Clinton election victory would be bad news for pharmaceutical stocks due to her promise to tackle exorbitant drug prices as president, today’s article argues that the prospect of Hillary in the White House isn’t what has pharmaceutical company CEOs and pharma-stock investors on edge. So what does have them worried, according to the author? A ballot measure in California which, if it passes, could lead to a protracted decline in the sector. What is California’s Proposition 61, how might it have a wider impact beyond California and what does it mean for pharma-stock investors? CLICK HERE to find out.